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Neural transplantation in neurodegenerative diseases such as Parkinson’s disease (PD)
offers to replace cells lost during the progression of the disease process. Primary fetal
ventral mesencephalon (VM), the origin of bona fide midbrain dopaminergic (DAergic)
precursors, is currently the gold standard source of cells for transplantation in PD.
However, the use of tissue from this source raises ethical and logistical constraints
necessitating the need for alternative supplies of donor cells. The requirement of
any alternative donor cell source is to have the capability to generate authentic
mature DAergic neurons, which could be utilized in cell-replacement strategies. Mouse
pluripotent stem cells can efficiently generate electrochemically mature midbrain DAergic
precursors in vitro using a stepwise control of FGF signaling. Here, we have compared
DAergic transplants derived from two progenitor cell sources in an allograft system:
mouse epiblast stem cells (EpiSC) and primary fetal mouse VM tissue. Cells were
transplanted into the striatum of 6-OHDA lesioned mice pre-treated with L-DOPA. Drug-
induced rotations, a number of motor tests and drug-induced abnormal involuntary
movements (AIMs) were assessed. Functional improvements were demonstrated post-
transplantation in some behavioral tests, with no difference in graft volume or the
number of TH immuno-positive cells in the grafts of the two transplant groups. L-
DOPA-induced AIMs and amphetamine-induced AIMs were observed in both transplant
groups, with no differences in rate or severity between the two groups. Collectively,
in this mouse-to-mouse allograft system, we report no significant differences in the
functional ability between the gold standard primary VM derived and pluripotent stem
cell-derived DAergic transplants.
Keywords: transplantation, Parkinson’s disease, dopaminergic neurons, primary fetal ventral mesencephalon,
stem cells
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INTRODUCTION
In Parkinson’s disease (PD), neural transplantation of midbrain
dopaminergic (DAergic) precursor cells aims to replace the nigral
DAergic supply to the striatum which is lost during progression
of this neurodegenerative disorder. Tissue taken from the region
of the developing fetal brain where midbrain DAergic neurons
originate, the ventral mesencephalon (VM), is currently regarded
as the “gold standard” source of cells for clinical cell-replacement
strategies in PD. Indeed, cells from primary fetal VM have
been utilized in clinical trials of neural transplantation and
have produced encouraging, albeit varied, results with respect to
graft survival, and reinnervation within the host striatum and
functional improvements (Lindvall et al., 1990, 1992; Mendez
et al., 2005; Barker et al., 2013). Following reports of graft side
effects, in particular graft-associated dyskinesias (Greene et al.,
1999; Freed et al., 2001; Olanow et al., 2003; Barker et al., 2013)
there was a pause in clinical fetal tissue transplants. Following
extensive metanalysis and discussion of existing trials and further
preclinical work (Barker et al., 2013, 2015; Parmar et al., 2019)
the TRANSEURO trial commenced in 2012 (ClinicalTrials.gov
NCT01898390). Results from the TRANSEURO trial are not
expected until 2021 at the earliest (Barker and TRANSEURO
consortium, 2019).
Animal models have provided much of the supporting data
on transplant efficacy and the implantation of primary mouse
VM into 6-OHDA lesioned mice has provided evidence of
graft survival and integration with demonstration of functional
improvements on various behavioral assessments (Shimizu et al.,
1990; Thompson et al., 2009; Heuer et al., 2013; Kauhausen
et al., 2013). The logistical issues surrounding the use of primary
fetal tissue for therapeutic intervention in any disease render
it complicated and impractical as a long-term prospective.
Advances in the pluripotent stem cell research field have provided
evidence that pluripotent stem cell-derived donor cells may
ultimately serve as a valuable alternative source of cells for
therapeutic application. Mouse pluripotent stem cells have been
shown to have the capability to differentiate into DAergic neurons
(Kim et al., 2002; Friling et al., 2009; Jaeger et al., 2011).
Transplantation of mouse embryonic stem (ES) cell-derived
DAergic precursors has resulted in survival and appropriate
differentiation of a proportion of grafted cells, with a degree of
rotational recovery (Kim et al., 2002; Rodriguez-Gomez et al.,
2007; Battista et al., 2014).
With respect to human pluripotent stem cells, following
application of systematic protocols DAergic precursor cells
have been differentiated in vitro and in vivo; generating
surviving grafts comprising DAergic neurons (Kriks et al., 2011;
Grealish et al., 2014; Niclis et al., 2017). DAergic transplants
derived from human ES cells have produced improvements
in amphetamine-induced rotations (Kriks et al., 2011; Grealish
et al., 2014; Niclis et al., 2017) and motor behaviors (Kriks
et al., 2011). Of note, the study by Grealish et al. (2014)
directly compared human primary fetal derived DAergic cells
with human ES cell-derived DAergic cells in an immuno-
deficient rat model of PD. They showed that transplanted human
ES cells generated grafts with similar outgrowth, survival, and
functional efficiencies to those generated from human fetal VM
cells. Furthermore, using the modified rabies tracing system
Grealish et al. (2015) have shown that human ES cell-derived
DAergic grafts form reciprocal synaptic connections with host
rat brain tissue.
One side effect of primary fetal dopamine transplants in
PD is the development of graft induced dyskinesias (GIDs) in
some patients (Freed et al., 2001; Hagell et al., 2002; Olanow
et al., 2003). There is a literature reporting research into
understanding the underlying causes and implications of graft-
mediated abnormal movements so as to improve longitudinal
outcomes following transplantation, with much mechanistic
insight established using abnormal involuntary movements
(AIMs) observed in the rat 6-OHDA lesion model (Carlsson et al.,
2006; Lane et al., 2006, 2008, 2009a,b, 2010; Soderstrom et al.,
2008, 2010; Steece-Collier et al., 2009; Lane and Smith, 2010;
Tronci et al., 2015). These studies establish that L-DOPA-induced
AIMs may change in the presence of the graft indicating early
function, that amphetamine may induce abnormal movements
which may be indicative of the potential for graft-induced
dykinesia, but that true spontaneous dyskinesia have not been
reliably observed. Previously, amphetamine induced AIMs have
been identified in a mouse allograft paradigm in which primary
mouse VM derived cells transplanted into the dopamine-depleted
striatum resulted in development of AIMs similar to those seen in
the rat model (Smith et al., 2012b).
Despite the increasing use of pluripotent stem cell-derived
midbrain DAergic precursors for cell replacement strategies in
animal models of PD, there is surprisingly limited literature
directly comparing this relatively new cell source with the
“gold standard” for neural transplantation that is primary
fetal VM tissue. The majority of current studies are also
confounded by the need for sustained immunosuppression and
transplantation into xenogenic species (typically human cells to
a rat host). Furthermore, there have been no studies comparing
transplantation of these cells in the presence of pharmacological
dopamine replacement strategies; medication that patients will
have been on for many years pre-operatively, and which the
majority will continue to be on post transplantation, albeit
often at a lower dose. Direct comparison of efficacy post
transplantation of pluripotent stem cell-derived grafts versus
their fetal counterparts, should be made in order to ascertain
more precisely how similarly or not DAergic precursors from
the different cell sources behave post-transplantation. Here, we
determined the efficiency of transplanted DAergic progenitor
cells derived from two cell sources: bona fide primary mouse
fetal VM tissue and mouse pluripotent stem cells that were
differentiated toward a DAergic phenotype, to rescue deficits
in the mouse 6-OHDA lesion model of PD. In addition, this
head-to head comparison of authentic DAergic precursors with
non-authentically derived DAergic precursors was carried out
in an allograft system circumventing the potential impact of
immunosuppression. Histological analyses were performed, and
functional recovery was assessed looking at (1) drug-induced
rotations; (2) a number of other motor tests of spontaneous
behaviors; and (3) drug-induced dyskinesias (scoring AIMs). We
found that, upon grafting, DAergic progenitors derived from
the two donor cell sources were equipotent in all aspects of
performance assessed.
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MATERIALS AND METHODS
Animals
All animal experiments were carried out in accordance with the
UK Animals (Scientific Procedures) Act 1986 and approved by
Local Ethics Review. Adult male mice (C57/Bl6) (Charles River,
United Kingdom) were housed in groups of 4–6 in standard cages
with a 12:12 h light:dark cycle and free access to food and water
ad libitum. All procedures and testing were performed during
the light phase.
6-OHDA Lesions and Transplantation
All surgical procedures were conducted under general anesthesia;
induced with 2–3% isoflurane in oxygen and maintained at
1–2% isoflurane in a 2:1 oxygen/nitrous oxide mix. Post-
operatively, mice were administered 0.5 ml saline solution
containing 4% glucose, and Metacam (0.5 mg/kg), both via
subcutaneous injection.
6-OHDA lesions were performed as previously described
(Heuer et al., 2012; Smith et al., 2012a). Briefly, mice received
unilateral 6-OHDA lesions to the medial forebrain bundle
(MFB) at the following stereotaxic coordinates: AP = −1.2 mm,
ML =−1.2 mm, and DV =−4.75 mm relative to bregma and the
dura surface, with the incisor bar set at the interaural line. One
microliter 6-OHDA was injected at a concentration of 6 µg/µl
(in 0.2 mg/ml ascorbic acid in 0.9% saline) at a flow rate of
1 µl/min using a 30-gauge stainless steel cannula connected via
fine polyethylene tubing to a Hamilton syringe on a microdrive
pump, and followed by a 3 min post-infusion interval period
where the cannula remained in situ.
Four to five weeks post-lesion, the lesion-induced deficit
was assessed according to drug-induced rotations following
administration of amphetamine (2.5 mg/kg; i.p.) and lesioned
mice were group-matched according to rotational scores: a
lesion only group and two transplant groups; primary VM and
EpiSC. Mice in the two transplant groups received unilateral,
intrastriatal transplants, ipsilateral to the lesion at the following
stereotaxic coordinates: AP = +0.8 mm, ML = −1.7 mm,
DV = −3.0 mm/−2.8 mm with the toothbar set at the interaural
line. Two microliters cell suspension (150,000 cells/µl) were
delivered using a Hamilton syringe, at 1µl/min at each of the two
heights. Following grafting, the needle was left at the graft site for
a further two min before a slow withdrawal.
Preparation of Cells for Transplantation
Primary fetal mouse tissue was obtained from C57/Bl6 female
mice at embryonic day (E) 12. The VM from each embryo
was dissected (based on Dunnett and Bjorklund, 1992) into
Hanks balanced salt solution (HBSS) (Gibco), and a single-
cell suspension was prepared. Briefly, HBSS was removed and
tissue was incubated in trypsin (Worthington)/DNAse (Sigma)
at 37◦C for 10 min. Trypsin inhibitor (Sigma) was added and
tissue was incubated at 37◦C for a further 5 min. DMEM/F12
(Gibco) was added and cells were harvested by centrifugation
at 1000 rpm for 3 min. The resulting pellet was resuspended in
200µl DMEM/F12, triturated to produce a single-cell suspension
and cells were counted using trypan blue exclusion. Cells were
resuspended in DMEM/F12 at a density of 150,000 cells/µl for
transplantation.
Mouse EpiSCs (EpiSC line Pitx3-LacZ) were differentiated
according to Jaeger et al. (2011). Briefly, mouse EpiSCs were
plated on fibronectin-coated plastics and cultured in N2B27
medium with bFGF (12 ng/ml, Peprotech) and activin A
(20 ng/ml, R&D). When cells reached ∼65% confluency, this
was designated as day 0 of monolayer differentiation. On day
0 cells were rinsed twice with phosphate-buffered saline (PBS)
and cultured in retinol-free N2B27 medium with addition of
PD0325901 (1 µM, Axon). The following day, half the medium
was replaced with fresh medium. On day 2 cells were gently
rinsed in PBS, mechanically dissociated in retinol-free N2B27
medium and seeded onto fresh fibronectin-coated plastic (1:3–6)
in retinol-free N2B27 medium with SHH (200 ng/ml, C25 II-N,
and R&D). Thereafter, medium was refreshed every other day.
From day 5, FGF8b (100 ng/ml, Peprotech) and SHH (200 ng/ml)
were added to the cultures. At day 7 of the differentiation
protocol medium was removed, cells were washed in PBS and
incubated in accutase (PAA Laboratories) at 37◦C for 2–3 min.
DMEM/F12 was added to the dish, cells were transferred to a
15 ml falcon tube and harvested by centrifugation at 1000 rpm
for 3 min. The resulting pellet was resuspended in 200 µl
DMEM/F12, triturated to produce a single-cell suspension and
cells were counted using trypan blue exclusion. Cells were
resuspended in DMEM/F12 at a density of 150,000 cells/µl for
transplantation.
Behavioral Analysis and Quantification
We assessed mice on a panel of behavioral tests previously
described in the 6-OHDA lesion mouse model (Heuer et al.,
2012; Smith et al., 2012a). Tests used here were balance
beam, rotarod, rotation, and AIMs. The investigator was
blind to which groups the mice had been assigned. Tests are
described in brief here.
Spontaneous Rotations
Spontaneous rotations were measured as previously
described (Heuer et al., 2012). The number of turns in
the ipsilateral and contralateral direction were recorded
and totaled. Data are represented as % of turns toward the
contralateral direction.
Elevated Balance Beam
Elevated balance beam was performed as previously described
(Heuer et al., 2012). Specifically, the time taken for the initial turn
and beam traversal were measured.
Rotarod
Rotarod was performed and analyzed as previously described
(Heuer et al., 2012). After training, mice were assessed for latency
to fall from the rotating beam using an accelerating protocol.
Amphetamine-Induced Rotations
Amphetamine-induced rotations were assessed following
administration of metamphetamine (2.5 mg/kg in 0.9%
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saline; i.p.). Mice were placed in glass beakers (as for
the spontaneous rotations), and turns were measured
using an automated rotometer system (Rotomax System,
AccuScan Instruments Inc.) for a period of 90 min. Data
are presented as average net rotations (ipsilateral minus
contralateral) every minute and analyzed at both the 20 min and
70 min time bin.
Abnormal Involuntary Movements
Abnormal involuntary movements were scored following
administration of L-DOPA (10 mg/kg, with 10 mg/kg benzerazide
HCl in 0.9% saline; s.c.) and metamphetamine (2.5 mg/kg in 0.9%
saline; i.p.). Mice were primed with daily L-DOPA injections
(s.c) for 21 days prior to grafting to establish dyskinesia at
baseline. Dyskinesia was equivalent in all lesioned groups prior
to transplantation. L-Dopa induced dyskinesias (LIDs) were then
scored again at 16 weeks post transplantation and AIMs were
compared to the lesion only group. All animals were scored once
every 20 min for 3 h.
The AIMs scoring criteria is based on the specific rating
scales (Winkler et al., 2002; Cenci and Lundblad, 2007; Smith
et al., 2012a,b). Duration and amplitude scores are the sum of all
forelimb, hindlimb, orolingual and axial AIMs at all time points in
the respective category. These are then in turn multiplied together
to give a total integrated AIM score.
Tissue Processing,
Immunohistochemistry, Imaging, and
Quantification
Mice were terminally anesthetized with sodium pentobarbital
and transcardially perfused with approx. 30 ml PBS followed
by 100 ml 1.5% paraformaldehyde (PFA) in PBS. Brains were
removed, post-fixed for 24 h in 1.5% PFA, cryo-protected in 25%
sucrose solution until they had sunk and were then sectioned
coronally on a freezing-stage microtome at 40 µm thickness.
Free-floating sections were processed for immunohistochemistry
using the primary antibodies anti-tyrosine hydroxylase (TH;
1:1000; Chemicon) and anti 5-HT (1:15,000; Immunostar Inc.);
biotinylated secondary antibodies; and ABC kit (Vectastain
Elite) and diaminobenzidine (DAB; Vector Laboratories) for
visualization, as previously described (Heuer et al., 2012).
Immuno-labeled sections were visualized under a Leica DM/RBE
light microscope and an Olympus BX50 light microscope
with Visiopharm Integrator System software (version 4.4.6.9).
For analysis of TH-fiber outgrowth, we adapted an existing
protocol (Bagga et al., 2008). TH immunopositive projections
were counted at 100 µm intervals from the periphery of the
graft, vertically and horizontally, at dorsal, ventral, medial, and
lateral aspects.
Statistical Analysis
Data was analyzed using Graph Pad Prism 7 software
or SPSS Version 25.0. When the full analysis revealed
significant differences, pairwise comparisons between groups
were undertaken using Bonferroni post hoc test with a p < 0.05
cut off for significance.
RESULTS
Generation of Cells for Transplantation
EpiSCs were cultured using a monolayer differentiation protocol
(Figure 1A), where stepwise manipulation of FGF signaling was
employed (Jaeger et al., 2011). Initially, PD0325901 was added
for 2 days to block FGF signaling, followed by addition of Shh
alone for 3 days and then from day 5 cells were exposed to both
Shh and Fgf8. Analysis of cells at day 7 revealed expression of
the neural precursor markers nestin and Otx2 (Figures 1B,C).
Specifically, cells at this stage expressed Dmrt5, Lmx1a, and
Foxa2 (Figures 1B,C). Further differentiation was undergone
with continued exposure of cells to Shh and Fgf8, and subsequent
addition of BDNF, GDNF, and ascorbic acid (AA) (Figure 1A).
Cells analyzed at day 14 showed maintained expression of Foxa2,
with expression of the neuronal marker TuJ1 and the DAergic
neuronal marker TH (Figure 1D).
DAergic progenitors were taken at day 7 of the monolayer
differentiation protocol and transplanted unilaterally into the
dopamine depleted adult mouse striatum for comparison with
primary VM derived DAergic progenitors via assessment of
behavioral recovery and histological analysis.
TH Expression in Grafts
DAergic precursors derived from primary VM and EpiSCs
yielded TH immuno-positive cells up to 16 weeks post-
transplantation (Figure 2A), with graft survival at 80% in both
transplant groups. The number of TH immuno-positive cells
per graft was similar in the two transplant groups (447 ± 154
for primary VM; and 474 ± 101 for EpiSCs) (t23 = 0.88,
n.s) (Figure 2B). Additionally, graft volume, defined by the
region of TH immune-staining, was not significantly different
between the two transplant groups (t23 = 0.99, n.s) (Figure 2C).
Moreover, there was no evidence of any graft overgrowth
in transplants of both the primary VM or the differentiated
EpiSC. Analysis of the morphology of the grafts revealed no
significant differences in the number of TH positive projections
extending from the grafts of the two transplant groups at any
distance [F(1,10) = 0.17, n.s] (Figure 2D). Grafts from both
groups demonstrated that with increased distance from the
graft the number of projections was lower [F(4,40) = 27.92,
p< 0.001].
Further analysis of the transplanted cells revealed a difference
in the morphological subtype of the neurons between the two
transplant groups [Chi-Square test: χ(2) = 7.636, p < 0.05].
Cells were assessed for the number of structures extending out
of the soma: 36% of VM-derived grafted cells were unipolar,
whereas 59% of EpiSC-derived grafted cells were unipolar; the
number of bipolar neurons were similar with 39% from VM-
derived and 36% from EpiSC derived grafted cells; and 25% of
VM-derived grafted cells were multipolar, whereas 5% of EpiSC
derived grafted cells were multipolar. Measurements of the cell
soma diameter and area of TH immunopositive transplanted
cells revealed differences between cells derived from the two
transplant groups (soma diameter: primary VM 28.65± 0.61µm;
EpiSC derived 24.79 ± 0.72 µm (t13 = 3.79, p < 0.01);
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FIGURE 1 | Characterisation of EpiSC monolayer differentiation. (A) Schematic of monolayer differentiation protocol. (B–D) Photomicrographs of immunofluorescent
cytochemistry of cells at day 7 (B,C) and day 14 (D). At day 7, EpiSCs expressed Dmrt5 (blue), Lmx1a (red), and Nestin (green) (B); and Foxa2 (blue), Otx2 (red), and
Nestin (green) (C). At day 14, EpiSCs expressed Foxa2 (blue), TuJ1 (red), and TH (green) (D). PD03, PD0325901; Shh, Sonic hedgehog; AA, ascorbic acid.
soma area: primary VM 153.92 ± 11.21 µm2; EpiSC derived
108.18± 6.75 µm2 (t13 = 3.73, p< 0.01).
The number of 5-HT immuno-positive cells per graft was low
and highly variable. There was no significant difference between
the two donor cell types (primary VM: 110.23 ± 91.86; EpiSC
derived cells: 119.42 ± 55.35) (t5 = 0.09, n.s), although it is
noteworthy that 5-HT immune-positive cells were only detected
in one third of surviving primary VM derived grafts but were
found in all surviving EpiSC derived grafts analyzed.
Behavioral Analysis
In order to determine whether grafts left to mature for 16 weeks
post-transplantation caused any functional recovery in hemi-
parkinsonian mice, we performed several behavioral tests as
previously defined in Heuer et al. (2012). Significant differences
were observed between groups on the rotarod test [F(3,39) = 5.64,
n.s]; post hoc tests confirmed that 6-OHDA lesioned mice had a
deficit on rotarod performance compared to unlesioned controls
(p < 0.05) (Table 1). This deficit was not recovered in mice with
primary VM transplants (p < 0.01), but was partially alleviated
in mice with EpiSC transplants (p < 0.05) (Table 1). Mice with
unilateral 6-OHDA lesions exhibit spontaneous rotational bias
when placed in cylinders, caused by dopamine released from
the intact side [F(3,39) = 2.75, p < 0.01; post hoc p < 0.05].
This deficit was sustained in both of the transplant groups post-
transplantation, with no significant difference observed when
compared with the lesion-only mice; yet the two transplant
groups were still significantly different from the un-lesioned
controls (posthoc comparisons: primary VM: p < 0.05; EpiSC:
p < 0.05) (Table 1). Further motor coordination assessments
were made using the balance beam. No deficits were found in
any of the groups in the time taken for mice to make the initial
turn to face the correct direction to initiate the test. However, 6-
OHDA lesioned mice showed an increased latency to traverse the
beam compared to unlesioned controls [F(3,39) = 4.16, p < 0.05;
post hoc p < 0.05]. This deficit persisted in transplanted animals
of both groups (primary VM: p< 0.05; EpiSC: p< 0.05) (Table 1).
Dopamine Neuron Transplantation
Partially Rescues Amphetamine-Induced
Rotations
A more pronounced rotational response can be observed in hemi-
parkinsonian mice following administration of amphetamine.
The 6-OHDA lesioned group displayed a higher net ipsilateral
rotational response over 90 min compared to transplanted
animals when the data were examined in 1 min bins (Figure 3A).
However, there was no significant difference in the average
net rotations at both 20 min [F(2,18) = 1.74, n.s] and 70 min
[F(2,18) = 4.16, 0.1 > p > 0.05] compared to lesioned controls
although a clear trend toward a reduction in ipsilateral rotations
and a predominance of contralateral rotations was evident
(Figure 3B). Taken together, these results suggest that both
VM and EpiSC dopamine neuron transplants were capable of
releasing dopamine when stimulated with amphetamine but
had a minimal effect on functional recovery and the most
sensitive tests for capturing modest effects were the rotarod and
amphetamine-induced rotations.
Dopamine Neuron Transplantation Did
Not Suppress l-Dopa Induced Dyskinesia
and Caused Graft-Induced Dyskinesia
Mice were treated with L-DOPA for 3 weeks prior to
transplantation (described in Smith et al., 2012a; Francardo
and Cenci, 2014). At 16 weeks post-transplantation mice were
challenged with a single injection of L-DOPA to determine if
one cell type was more prone to provoke LIDs than the other by
assessing AIMs. AIMs were observed in all lesioned mice (lesion
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FIGURE 2 | Expression of TH in transplants of VM and EpiSC derived DA progenitors at 16 weeks post-transplantation. (A) Photomicrographs of histological
sections from mouse brains transplanted with VM derived DA progenitors and EpiSC derived DA progenitors, showing TH immunoreactivity. Higher magnification
images reveal TH immune-positive cells within the grafts. Bar charts showing: (B) the average number of TH immuno-positive cells per graft; (C) the graft volume;
and (D) the number and distance of TH projections. Error bars represent standard error of the mean.
only and lesion plus transplant) compared to unlesioned control
mice from 20 to 140 min post-injection (Figure 4A). Significant
differences between groups were observed [F(3,42) = 4.70,
p < 0.01]. Average AIMs were significantly increased in the
6-OHDA lesioned group compared to unlesioned controls as
expected (p = 0.045), and were also elicited in both transplant
groups: primary VM (p < 0.01) and EpiSC derived (p < 0.05)
(Figure 4B). AIM subtypes were then analyzed separately
and significant differences between the groups were observed
[F(3,168) = 14.22, p < 0.001]. L-DOPA induced AIMs of the hind
limb were observed in VM (p < 0.01) and EpiSC (p < 0.05)
transplanted mice, which were minimal in unlesioned controls
(Figure 4C). This was also seen for forelimb AIM quantification
(VM: p < 0.01; EpiSC: p < 0.05) (Figure 4C). L-DOPA
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TABLE 1 | Assessment of behavioral tests.
Un-lesioned control Lesioned control Primary VM EpiSC
Rotarod (secs)1 135.4 ± 10.57 84.1 ± 12.7* 74.5 ± 12.5** 99.4 ± 10.5#
Spontaneous rot (% contralateral)1 48.9 ± 2.8 29.7 ± 8.9* 22.0 ± 9.1* 27.2 ± 7.8*
Beam traversal (latency)1 7.66 ± 0.42 12.7 ± 0.89* 16.17 ± 2.42* 15.65 ± 3.02*
Assessments performed at 16 weeks post-transplantation. 1Data is presented as mean ± SEM and was analyzed by one-way ANOVA using Tukey post hoc tests.
Significance is annotated as ∗p < 0.05 and **p < 0.001 compared to un-lesioned controls and #p < 0.05 compared to lesioned controls.
FIGURE 3 | Assessment of drug induced rotations. (A) Total net rotations were recorded every min for 90 min following Amphetamine (Amphet) injection.
(B) Average net rotations at both 20 and 70 min were increased in lesioned animals although not significantly, with little change in transplanted (VM) and transplanted
(EpiSC) groups. Data was analyzed by 1-way ANOVA (p < 0.07 at 70 min). Graphs are expressed as Mean ± SEM and N = ≥ 6 mice per group.
induced AIMs were also observed in the axial category (lesioned:
p < 0.001; VM: p < 0.001; EpiSC: p < 0.01), yet no orolingual
AIMS were observed (lesioned: p = n.s; VM: p = n.s; EpiSC:
p = n.s) (Figure 4C). AIMs were not correlated to the number
of TH neurons in the grafts (VM: p = n.s; EpiSC: p = n.s)
(Figure 4D).
Rodent recipients of DAergic transplants can also develop
a form of GID when administered amphetamine. Whilst LID
did not distinguish between lesion only and transplanted
mice, hemi-parkinsonian mice receiving primary VM and
EpiSC derived dopamine precursors showed clear amphetamine
induced AIMs following administration of amphetamine which
were not elicited in the unlesioned and lesion only control mice
[F(3,42) = 5.55, p < 0.01] (Figure 4E). Pairwise comparisons
indicated that average AIMS were significantly greater following
primary VM (p < 0.05) and EpiSC derived (p < 0.01)
dopamine precursor transplantation (Figure 4F). Significant
differences were also observed for amphetamine driven AIMs
when quantified per anatomical subcategory [F(3,168) = 16.05,
p < 0.001]. Sterotyped movements of the hind limb were
significantly increased in primary VM (p < 0.01) and EpiSC
(p < 0.01) transplanted mice compared to unlesioned controls
(Figure 4G). This increase was also seen in the forelimb (VM:
p < 0.05 and EpiSC: p < 0.01), yet axial AIMs were only
significantly increased by EpiSC derived dopamine precursor
transplantation (p < 0.001) (VM: p = n.s) (Figure 4G).
No significant levels of orolingual AIMs were observed
in any treatment group (VM: p = n.s; EpiSC: p = n.s)
(Figure 4G). Amphetamine stimulated AIMs were not correlated
to the number of TH + ve neurons in the grafts (VM:
p = n.s; EpiSC: p = n.s) (Figure 4H). These data suggest
that GIDs may occur following transplantation regardless of
dopamine neuron source.
DISCUSSION
Efficient generation of midbrain DAergic precursors in vitro
has been shown by employment of a stepwise control of
FGF signaling (Jaeger et al., 2011). Precursor cells, at day
7 of the differentiation protocol (the day that cells were
harvested for transplantation in our study), expressed Dmrt5,
Lmx1a, and Foxa2 which are characteristic markers of midbrain
DAergic neural progenitors (Andersson et al., 2006; Ferri
et al., 2007; Gennet et al., 2011). Mature neurons differentiated
using this protocol expressed TH and showed functional
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FIGURE 4 | Assessment of abnormal involuntary movements (AIMS). (A) AIMS were recorded every 20 min following L-Dopa injection. (B) Average AIMS were
significantly increased in lesioned, transplanted (VM), and transplanted (EpiSC) following L-Dopa. (C) L-Dopa induced AIMS of the hind limb (HLi), fore limb (FLi), and
Axial (Ax) were increased in all experimental groups compared to control. (D) L-Dopa induced dyskinesia was not correlated by grafted TH +ve cell number. (E) AIMS
were recorded every 20 min following amphetamine (Amphet) injection. (F) Average AIMS were significantly increased in lesioned, transplanted (VM), and
transplanted (EpiSC) following Amphet. (G) Amphet induced AIMS of the hind limb (HLi), fore limb (FLi), and Axial (Ax) were significantly increased in all experimental
groups compared to control. (H) Graft-induced dyskinesia was not correlated by grafted TH +ve cell number. Data was analyzed by 1-way ANOVA and significant
differences annotated as *p < 0.05, **p < 0.01, and ***p < 0.01 compared to control. For A and E data was analyzed by MANOVA and significance annotated as
*p < 0.05 and **p < 0.01 compared to control. Graphs are expressed as Mean ± SEM and N = ≥ 6 mice per group.
neuron-like electrophysiological properties (Jaeger et al., 2011).
Furthermore, following 14 days of differentiation, around 50%
of neurons were TH positive, and of the TH-positive cells,
around 70% were immunopositive for Pitx3, another marker of
midbrain DAergic neurons (Jaeger et al., 2011). We investigated
these cells in vivo, assessing their functional capability in a
direct comparison to the current gold standard for DAergic
transplants: authentic DAergic progenitors harvested from
primary fetal VM.
Despite the fast-moving pace of the stem cell field in the
progression of differentiation protocols for generation of specific
neuronal phenotypes for research into neurodegenerative disease
for disease-in-a-dish paradigms and cell replacement strategies
(including DAergic neurons for PD), there is limited literature
on comparisons of in vivo performance of stem cells with their
primary fetal neural tissue counterparts. In particular, and of
note in the PD model system, there is little utilization of the
mouse model, which means that since rat pluripotent stem
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cells are not well-established, there is limited experience of
transplantation in an allograft model system. Here, we carried
out a direct comparison of allografts of primary fetal VM
derived and EpiSC derived DAergic precursors transplanted
into a hemi-parkinsonian mouse model. At 16 weeks post-
transplantation we demonstrated surviving DAergic grafts with
no sign of overgrowth or teratoma formation in either group.
Our histological analyses showed no differences in the grafts
yielded by the two transplant groups with respect to number of
TH immuno-positive cells and graft volume. We also recorded
no difference in the distance that TH positive cells projected
outward from the grafts of both donor cell groups. These findings
are consistent with those of Yurek and Fletcher-Turner (2004)
who also demonstrated no difference in innervation of TH
outgrowth in the striatum from DAergic grafts derived from
both primary fetal VM and ES cells. In our analysis of the
morphology of the graft-derived TH-positive cells we showed
that the majority of cells in the EpiSC grafts were unipolar
with only a small proportion of multipolar neurons. In contrast,
graft-derived neurons from the primary VM transplant group
were more evenly distributed between unipolar, bipolar, and
multipolar subtypes. In addition, we identified a difference in
the cell soma size between the two groups of grafted DAergic
neurons. Specifically both the diameter and area of the cell soma
were larger in the primary VM derived neurons compared with
the EpiSC derived DAergic neurons. Differences in neuronal
morphology may be important in the functionality of the graft,
however, this warrants further investigation.
With respect to 5-HT, we identified a small population of
5-HT immuno-positive neurons within both VM and EpiSC
grafts, present in similar proportions. In VM tissue transplants,
5-HT neurons are incorporated if there is a wider caudal
dissection encompassing some of the developing raphe nuclei.
The population of 5-HT neurons within a graft is of interest
as there has been speculation about their role in graft-induced
dyskinesia (Lane et al., 2009b; Politits et al., 2010; Politis et al.,
2011), and although this has not been conclusively demonstrated
to be a concern, protocols for future clinical trials are dedicated
to generating specific DAergic lineages which in effect eliminate
the risk 5-HT neurons may contribute (Barker et al., 2017). There
is, however, no evidence that the 5-HT neurons contribute to the
functional efficacy of the graft.
It is known that DAergic neurons in the transplant are
necessary to achieve recovery on the amphetamine-rotation task
(Dunnett et al., 1988) and functional improvement on this task
directly corresponds to synaptic dopamine release. In addition,
it is thought that in vivo performance of transplantation relies
upon appropriate DAergic number, subtype and outgrowth
into the dorsolateral striatum, reviewed in Peng and Copray
(2016). This has been extensively studied following primary
tissue transplants in rodents, but studies which show functional
recovery with stem cell transplants can be limited, in particular
in the mouse model. One previous study showed that mouse
ES cells transplanted into 6-OHDA lesioned rats did not
induce functional recovery compared to primary mouse
fetal VM transplantation, despite yielding similar DA cell
numbers and morphologies (Yurek and Fletcher-Turner, 2004).
However, over recent years it has been suggested that ES
cells can have comparable properties to primary tissue in
immunocompromised rats, indicating that long term functional
improvements are possible (Grealish et al., 2014). In addition, it
has been shown that DA release measured through microdialysis
is higher in rodents that had received DAergic transplants derived
from ES cells compared with lesion only controls, corresponding
to improved amphetamine-induced rotations (Rodriguez-
Gomez et al., 2007). We demonstrate that functional stem cell
grafts are possible in mice that are not immunosuppressed,
demonstrated by enhanced rotarod performance, increased
amphetamine-induced rotation and decreased L-DOPA-induced
dyskinesia. However, further optimisation is needed to increase
the beneficial effect in order to alleviate fine motor deficits on
behavioral tests such as balance beam. ES cell differentiation
protocols, transplantation procedures and animal model
choices may therefore be key to induction of functional
recovery.
In this direct comparison of transplantation of DAergic
neurons derived from a pluripotent stem cell source with
primary fetal DAergic progenitors from VM we used mouse
donor cells and mouse graft recipients to circumvent the need
for immunosuppression. Through multiple behavioral tasks,
previously shown to be useful in assessing the 6-OHDA MFB
lesion in mice (Heuer et al., 2012), we found impairments
on the rotarod and balance beam tasks, with a significant
rotational bias over unlesioned, control mice both spontaneously
and in response to amphetamine. Evaluation of motor (Heuer
et al., 2013), cognitive (Heuer et al., 2013), and dyskinetic
behaviors (Smith et al., 2012b) have been reported following
transplantation of primary mouse VM derived DAergic cells.
Whilst there have been some direct comparisons of primary
versus pluripotent stem cell derived DAergic cells transplanted
in the 6-OHDA model (Grealish et al., 2014), this study is
distinct in that it uses species compatible donor cells and
alongside assessment of functional recovery also evaluates both
L-DOPA and amphetamine-induced AIMs. We observed modest
functional recovery which was mirrored in both transplant
groups. The most sensitive tests for capturing modest effects
in mice were the rotarod and amphetamine induced rotation.
Of note, the EpiSC transplant group, and not the primary VM
transplant group, showed a degree of recovery on the rotarod
at 16 weeks post-transplantation, with latency to fall no longer
significantly different from that of the unlesioned control group.
Importantly, the majority of literature on the 6-OHDA lesion
model with subsequent dopamine precursor transplantation to
assess functional recovery is in the rat (Yurek and Fletcher-
Turner, 2004; Rodriguez-Gomez et al., 2007; Peng and Copray,
2016; Bjorklund and Dunnett, 2019). There needs to be further
optimisation of transplantation procedures and behavioral tests
for functional readout in the mouse which will afford greater
flexibility to explore genetic influences without the complications
of immunosuppression.
Graft induced dyskinesias were first identified by Freed at
al following transplantation of human fetal VM tissue into
PD patients (Freed et al., 2001) and subsequently observed
following another US trial as well as retrospectively in a
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European trial (Hagell et al., 2002; Olanow et al., 2003). They
can occur despite a beneficial reduction in LIDs seen following
transplantation in experimental models (Carlsson et al., 2009;
Lane et al., 2009a). Since identification of this side effect there
has been much research to understand GIDs, so that they
may mitigated in future trials. Experimentally, behaviors aligned
to GIDs can be triggered in grafted 6-OHDA lesioned rats
by administration of amphetamine (Lane and Smith, 2010).
Amphetamine-induced AIMs have been found to be associated
with L-DOPA priming, graft composition, graft placement, size,
and potentially synaptic plasticity (Carlsson et al., 2006; Lane
et al., 2006, 2009a; Carta et al., 2010; Rylander Ottosson and
Lane, 2016). We previously generated a model for amphetamine-
induced AIMs in the 6-OHDA lesioned, L-DOPA treated mouse
demonstrating induction of these behaviors 16 weeks after
transplantation of primary mouse VM (Smith et al., 2012b).
Here, despite limited functional efficacy and no meaningful
reduction in L-DOPA induced AIMs compared to lesion-only
controls, amphetamine-induced AIMs were established equally
in both transplant groups. Importantly the magnitude of the
amphetamine-induced AIMs was significantly less than the
L-DOPA induced AIMs, consistent with reports from patients
that GID in the majority of cases was mild in severity (Hagell
et al., 2002). Induced in both transplant groups equally, it may
be that GIDs are an inevitable risk following transplantation
regardless of the donor cell source. If transplantation can be
optimized to provide reliable and meaningful improvements
in motor function and reductions in L-DOPA medication, the
benefits could far outweigh the potentially mild graft-induced
motor side effects which are significantly less troublesome than
LIDs which are an inevitability for the majority of patients
under current treatment options. Evidence from other studies
suggests that these could be mitigated by selecting patients
with well-defined denervation and limited LID development
with current medication (Piccini et al., 2005; Lane et al.,
2009a; Barker et al., 2017). Importantly, here we present data
validating the mouse 6-OHDA model for dyskinesia research
following pluripotent stem cell transplantation for the first
time.
We report differences in the morphology and cell soma
of VM-derived and EpiSC-derived DAergic neurons following
transplantation with no differences in the numbers of TH
immunopositive cells or their innervation into the host striatum.
With respect to functional assessment of the grafts, we present no
obvious differences between primary VM and EpiSC transplants
on the parameters investigated indicating that pluripotent stem
cell sources offer a realistic option for future transplantation
clinical trials for PD and given the right conditions and further
optimisation they may be able to be utilized as a long-lasting
dopamine replacement strategy. Pluripotent stem cell sources
have benefits over primary tissue because they side-step some
of the key issues intrinsic to fetal tissue: supply, quantity, and
consistency. Their production can be scaled up with batch
production and they can be potentially grown in bioreactors and
banked frozen until required (Nolbrant et al., 2017; Wakeman
et al., 2017). Robust differentiation protocols can be quality
assessed at critical stages using identification markers of authentic
differentiation, and microbiology testing, to ensure acceptable
standards are met (Kirkeby et al., 2017).
It will be important in future studies to optimize transplant
parameters in order to maximize functional recovery whilst
minimizing adverse effects. Strategies may include optimisation
of the cellular composition of the donor source, donor cell
number, graft location, and delivery method, etc. In order to
realize the potential for clinical application of pluripotent stem
cells further understanding of their in vivo capabilities compared
with the gold standard primary VM in an allograft model is
required. This would include stringent assessment of function,
including evaluation of the potential to produce dyskinesias.
Since there is an abundance of mouse and human PSC lines
and very few robust rat PSC lines, transplantation of PSCs in an
allograft system is most likely in the mouse, as presented here.
Allograft studies will be invaluable in enabling us to gain further
insight into the differences and similarities in the functional
properties of different cell sources following engraftment into the
disease host brain.
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